Anzahl der Publikationen: 7
Zeitschriftenartikel
Haas, M.; Siveke, J. T.; Schenk, M.; Lerch, M. M.; Caca, K.; Freiberg-Richter, J.; Fischer von Weikersthal, L.; Kullmann, F.; Reinacher-Schick, A.; Fuchs, M.; Kanzler, S.; Kunzmann, V.; Ettrich, T. J.; Kruger, S.; Westphalen, C. B.; Held, S.; Heinemann, V. und Böck, S.
(2018):
Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'.
In: European Journal of Cancer, Bd. 94: S. 95-103
Elander, N. O.; Aughton, K.; Ghaneh, P.; Neoptolemos, J. P.; Palmer, D. H.; Cox, T. F.; Campbell, F.; Costello, E.; Halloran, C. M.; Mackey, J. R.; Scarfe, A. G.; Valle, J. W.; McDonald, A. C.; Carter, R.; Tebbutt, N. C.; Goldstein, D.; Shannon, J.; Dervenis, C.; Glimelius, B.; Deakin, M.; Charnley, R. M.; Anthoney, Alan; Lerch, M. M.; Mayerle, J.; Olah, A.; Büchler, M. W. und Greenhalf, W.
(2018):
Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer.
In: British Journal of Cancer, Bd. 118, Nr. 7: S. 947-954
Elander, N. O.; Aughton, K.; Ghaneh, P.; Neoptolemos, J. P.; Palmer, D. H.; Cox, T. F.; Campbell, F.; Costello, E.; Halloran, C. M.; Mackey, J. R.; Scarfe, A. G.; Valle, J. W.; McDonald, A. C.; Carter, R.; Tebbutt, N. C.; Goldstein, D.; Shannon, J.; Dervenis, C.; Glimelius, B.; Deakin, M.; Charnley, R. M.; Anthoney, A.; Lerch, M. M.; Mayerle, J.; Olah, A.; Buchler, M. W. und Greenhalf, W.
(2018):
Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy.
In: British Journal of Cancer, Bd. 118, Nr. 8: S. 1084-1088
Stecher, S. S.; Simon, P.; Friesecke, S.; Glitsch, A.; Kühn, J. P.; Lerch, M. M. und Mayerle, J.
(2017):
Delayed severe bleeding complications after treatment of pancreatic fluid collections with lumen-apposing metal stents.
In: Gut, Bd. 66, Nr. 10: S. 1871-1872
[PDF, 341kB]
Michl, M.; Stintzing, S.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Al-Batran, S.-E.; Heintges, T.; Lerchenmüller, C.; Kahl, C.; Seipelt, G.; Kullmann, F.; Stauch, M.; Scheithauer, W.; Hielscher, J.; Scholz, M.; Mueller, S.; Lerch, M. M.; Modest, D. P.; Kirchner, T.; Jung, A. und Heinemann, V.
(2016):
CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)(aEuro).
In: Annals of Oncology, Bd. 27, Nr. 8: S. 1565-1572
Diese Liste wurde am
Sat Feb 15 20:09:04 2025 CET
erstellt.